Live Coverage from AES 2017
Clobazam is currently FDA-approved for the treatment of seizures associated with Lennox-Gastaut syndrome in children 2 years and older.
The diagnostic tool may be especially useful in cases of nonlesional mesial temporal lobe epilepsy.
Patients with refractory epilepsy who fail to benefit from 2 or more AEDs should be referred to alternative therapies.
Patients who died from suspected SUDEP had extensive damage to areas of the mid-brain and brainstem that control autonomic function.
Continuous Infusion in Refractory Status Epilepticus Linked to Increased Mortality, Longer Hospital Stay
Researchers compared outcomes between patients treated with continuous infusion or repeated doses of nonbenzodiazepine anti-seizure medication.
Cannabidiol Effective for Reducing Drop Seizures in Lennox-Gastaut Syndrome Regardless of Clobazam Use
The study was a post-hoc analysis of responders who were on or off concomitant clobazam.
Patients undergoing treatment for ischemic stroke are at greater risk for seizure development.
Treatment with positive airway pressure may help retain or improve seizure control in patients with epilepsy and obstructive sleep apnea.
Treatment algorithms are needed for patients with epilepsy who present with evidence of bone loss.
Researchers examined whether there are clinical features or treatments associated with neuropsychiatric outcomes in BECTS.
Sign Up for Free e-newsletters
Check out what's trending
Neurology Advisor Articles
- Vitamin D3 Associated With Reductions in Migraine Days Among Migraineurs
- Hemicrania Continua: Diagnosis and Treatment
- Predicting Outcomes in Parkinson Disease: Utility of EEG
- Psychiatric Adverse Effects from Levetiracetam Linked to Certain Factors
- Prolonged Aura in Migraine Linked to More Sensory Symptoms